Screener
Axsome Therapeutics AXSM EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's EBITDA?
- Axsome Therapeutics (AXSM) reported EBITDA of -$61.67M in Q1 2026.
- How has Axsome Therapeutics's EBITDA changed year-over-year?
- Axsome Therapeutics's EBITDA decreased by 11.6% year-over-year, from -$55.26M to -$61.67M.
- What is the long-term trend for Axsome Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EBITDA has grown at a 6.4% compound annual growth rate (CAGR), from -$124.63M to -$159.88M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Axsome Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude